Plus Therapeutics PSTV 深 沪
等待开盘 06-26 09:30:00 美东时间
4.27
+0.310
+7.83%
华盛通- 最 高4.40
- 今 开4.01
- 成交量 102.26万股
- 最 低 3.8784
- 昨 收 3.96
- 总市值 9.48万
- 52周最高 8.00
- 市盈率 静 --
- 换手率 4606.93%
- 52周最低 0.129
- 委 比 -99.68%
- 总股本 2.22万
- 历史最高 22.89
- 量 比 5.59
- 振 幅 13.17%
- 历史最低 0.129
- 每 手 1
- 风险率 2.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Plus Therapeutics Announces 1-For-25 Reverse Stock Split, Effective April 2
Plus Therapeutics, Inc. (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the
03-31 19:32
Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges
Plus Therapeutics stock falls in premarket trading after pricing a $15 million public offering, with proceeds set for working capital as the company develops cancer treatments.
01-15 00:36
Nasdaq Falls Over 100 Points; Bank of America Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more t...
01-14 22:40
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Shares of Bark Inc (NYSE:BARK) rose sharply in pre-market trading after a 13D f...
01-12 17:34
Plus Therapeutics Unit Expands Reach as CNSide Cancer Test Nears Nationwide Availability
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with
2025-12-11 20:34
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
Plus Therapeutics received a delinquency notice from Nasdaq due to delayed filing of its Q1 2025 report, requiring a compliance plan by July 21, 2025, to avoid delisting. The company aims to regain compliance promptly.
2025-05-23 20:15
Plus Therapeutics Continues Rally On Friday - Here's Why
Plus Therapeutics stock rises after peer-reviewed publication of Phase 1 glioma data and FDA Orphan Drug Designation for lung cancer treatment.
2025-03-07 22:30
US Stocks Likely To Open Higher After Nasdaq 100 Enters Correction Zone: 'Economic Resilience Provides A Foundation For Market Stabilization,' Says Expert
U.S. stock futures rose on Friday following Thursday's selloff that pushed the Nasdaq 100 index into the correction zone.
2025-03-07 18:47
Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $20
Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from $21 to $20.
2024-09-03 17:34
